Logo

AstraZeneca Reports Updated Results of Imfinzi (durvalumab) in P-III PACIFIC Trial for Non-Small Cell Lung Cancer

Share this

AstraZeneca Reports Updated Results of Imfinzi (durvalumab) in P-III PACIFIC Trial for Non-Small Cell Lung Cancer

Shots:

  • The P-III PACIFIC trial involves assessing Imfinzi vs PBO in 713 patients with unresectable- stage III NSCLC whose disease had not progressed following concurrent platinum-based CRT in 235 centers across 26 countries
  • The updated post-hoc analyses demonstrated OS @5yrs. (42.9% vs 33.4%)- m-OS (47.5 vs 29.1mos); at the treatment course of one year patients had not progressed after 5yrs. (33.1% vs 19%) respectively. The results were presented at ASCO 2021
  • The therapy is approved for the treatment of ES-SCLC based on the P-III CASPIAN trial in the EU- US- Japan- and other countries globally and approved for previously treated patients with advanced bladder cancer in several countries

  | Ref: Business Wire | Image: Business Standard

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions